Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma August 2, 2023
Ongoing Double-Digit ORR observed for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial June 28, 2023
3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine June 28, 2023
225 patients randomized in Phase 3 clinical trial for IO102-IO103, in combination with KEYTRUDA in patients with advanced melanoma June 21, 2023
mRNA-4157 (V940) + KEYTRUDA Combination Demonstrated a Statistically Significant DMFS Improvement in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA June 14, 2023
IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma May 31, 2023
Type A Meeting Request submitted to FDA to Review Proposed Study Design for a Second Ph 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma May 10, 2023
Positive Interim Ph 2 Data for Darovasertib + Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in 1L Metastatic Uveal Melanoma announced May 10, 2023
Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA in a Ph 1b Clinical Trial in Melanoma April 20, 2023
mRNA-4157 (V940) + KEYTRUDA combination Demonstrated Superior RFS in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection vs KEYTRUDA April 20, 2023
Clinical Data of KEYNOTE-695 Trial of TAVO™-EP + KEYTRUDA in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment announced April 12, 2023
mRNA-4157/V940 (mRNA Cancer Vaccine + KEYTRUDA) Receives PRIME Scheme Designation from the EMA for Adjuvant Treatment of Patients with High-Risk Stage III/IV Melanoma Following Complete Resection April 12, 2023
Merck Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab) March 31, 2023
FDA accepts Supplemental BLA and EMA Validates Application for Opdivo as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma March 15, 2023
Kinnate Biopharma Acquires Ownership Stake from Kinnjiu Biopharma; Initiates Ph 1 Trial for Exarafenib (KIN-2787) in China February 28, 2023
mRNA-4157/V940 + KEYTRUDA® combo Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection February 28, 2023
BLA submitted to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma January 11, 2023
Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs December 19, 2022
